Magnetic resonance imaging (MRI), one of the most general
imaging
techniques in the clinic, is widely employed for tumor diagnosis with
the assistance of contrast agents (CAs). However, currently available
CAs in the clinic suffer from shortcomings of a short blood circulation
time, lack of specificity to pathological location, insufficient imaging
window, and potential biotoxicity of the gadolinium ion. To overcome
these problems, on the basis of extremely small iron oxide nanoparticles
(ESIONPs), a hypoxia-responsive T1-to-T2 switchable
MRI contrast agent was designed and constructed. In detail, polyacrylic
acid-modified ESIONPs (ESIONPs-PAA) were first synthesized, and then,
nitroimidazole derivatives and cysteine molecules were sequentially
coupled on the surface of ESIONPs-PAA to obtain a hypoxia-responsive
MRI contrast agent (HR-ESIONPs). Since 2-nitroimidazole and cysteine
molecules on the surface of HR-ESIONPs can form an irreversible bond
induced by the nitroreductase in the hypoxic tumor microenvironment,
monodispersed HR-ESIONPs could transform into the nanocluster form,
which can specially provide T2 contrast enhancement. In vitro experiments show that monodispersed HR-ESIONPs
could effectively aggregate in the mimical hypoxic environment of
tumors and switch from a T1 to T2 contrast agent.
Moreover, in vivo experiments further confirm that
HR-ESIONPs could effectively accumulate and realize the MRI signal
switch from T1 to T2 contrast enhancement in
tumors originating from the aggregation of HR-ESIONPs induced by the
hypoxic environment, which promotes the diagnostic precision of tumors.
Additionally, with the confirmation of favorable biosafety on cells
and mice, hypoxia-responsive HR-ESIONPs are potential platforms to
improve the diagnostic accuracy and sensitivity of MRI for tumors.